References
  1. Blum FR, Sigmon JR. Successful treatment of Brunsting-Perry pemphigoid with dupilumab. JAAD Case Rep . 2021 Feb 23;10:107-109. doi: 10.1016/j.jdcr.2021.02.010. PMID: 33850992; PMCID: PMC8022106.
  2. Zhou S, Zou Y, Pan M. Brunsting-Perry pemphigoid transitioning from previous bullous pemphigoid. JAAD Case Rep . 2020 Feb 19;6(3):192-194. doi: 10.1016/j.jdcr.2019.12.018. PMID: 32149175; PMCID: PMC7033299.
  3. William DJ, Dirk ME, James RT, Misha AR, Isaac MN. Andrews’ Diseases of The Skin: Clinical Dermatology, Elsevier; 2020.
  4. Brunsting LA, Perry HO. Benign pemphigold; a report of seven cases with chronic, scarring, herpetiform plaques about the head and neck.AMA Arch Derm. 1957 Apr;75(4):489-501. doi: 10.1001/archderm.1957.01550160015002. PMID: 13410108.
  5. Kourosh AS, Yancey KB. Therapeutic approaches to patients with mucous membrane pemphigoid. Dermatol Clin. 2011 Oct;29(4):637-41. doi: 10.1016/j.det.2011.06.022. PMID: 21925010.
  6. Eichhoff G. Brunsting-Perry Pemphigoid as Differential Diagnosis of Nonmelanoma Skin Cancer. Cureus. 2019 Aug 16;11(8):e5400. doi: 10.7759/cureus.5400. PMID: 31620323; PMCID: PMC6793596.
  7. Vinay K, Kanwar AJ, Mittal A, Dogra S, Minz RW, Hashimoto T. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris. JAMA Dermatol. 2015 Aug;151(8):878-82. doi: 10.1001/jamadermatol.2014.3674. Erratum in: JAMA Dermatol. 2015 Jun;151(6):680. PMID: 25536513.
  8. Baffa ME, Corrà A, Maglie R, Mariotti EB, Montefusco F, Pipitò C, Senatore S, Quintarelli L, Caproni M, Antiga E. Rituximab in Mucous Membrane Pemphigoid: A Monocentric Retrospective Study in 10 Patients with Severe/Refractory Disease. J Clin Med. 2022 Jul 15;11(14):4102. doi: 10.3390/jcm11144102. PMID: 35887866; PMCID: PMC9325091.